Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety

PLoS Medicine 2026 Open access

Read full text
Authors: Ariana M. Chao, Adam H. Gilden, Thomas A. Wadden
DOI: 10.1371/journal.pmed.1004871
Cited by: 10
References: 9

Abstract

Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.

Fields of Study & Subjects

Diabetes Treatment and Management Bariatric Surgery and Outcomes Hyperglycemia and glycemic control in critically ill and hospitalized patients

Publication details

Journal / source
PLoS Medicine
Publisher
Public Library of Science (PLoS)
Volume
23
Issue
1
Pages
e1004871–e1004871
Publication date
14 January 2026
Language
EN